Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Men with Advanced Prostate Cancer

– ORGOVYX is the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Approved for Advanced Prostate Cancer in Canada – MISSISSAUGA, Ontario, Oct. 23, 2023 /PRNewswire/ — Sumitomo Pharma Canada, Inc., announced today that Health Canada has approved ORGOVYX®…